Search research articles
Contact Us
Filters
Showing results (21-30 of 136) with videos related to
Page
of 14
Sort By:
Investigational New Drugs
|
April 24, 2013
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
Aung Naing, Siqing Fu, Ralph G Zinner, et al.
The American Journal of Dermatopathology
|
August 11, 2012
Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor
Jonathan L Curry, Gerald S Falchook, Wen-Jen Hwu, et al.
JAMA Dermatology
|
April 5, 2013
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib
Gerald S Falchook, Peter Rady, Sharon Hymes, et al.
Neuro-Oncology Advances
|
February 10, 2025
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma
Gerald S Falchook, James D Battiste, Amandeep Kalra, et al.
Cancer Immunology, Immunotherapy : CII
|
September 29, 2020
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Kyriakos P Papadopoulos, Nehal Lakhani, Gerald S Falchook, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 5, 2021
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
Wenyuan Xiong, Manja Friese-Hamim, Andreas Johne, et al.
Oncotarget
|
July 11, 2018
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors
Ishwaria M Subbiah, Chad Tang, Arvind Rao, et al.
ESMO Open
|
February 22, 2018
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
Kathleen N Moore, Todd M Bauer, Gerald S Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2014
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer
Gerald S Falchook, Nelson G Ordóñez, Christel C Bastida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2010
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
Ignacio Garrido-Laguna, Filip Janku, Gerald S Falchook, et al.
Page
of 14
Search research articles
Search
Showing results (21-30 of 136) with videos related to
Sort By:
Page
of 14
Investigational New Drugs
|
April 24, 2013
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
Aung Naing, Siqing Fu, Ralph G Zinner, et al.
The American Journal of Dermatopathology
|
August 11, 2012
Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor
Jonathan L Curry, Gerald S Falchook, Wen-Jen Hwu, et al.
JAMA Dermatology
|
April 5, 2013
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib
Gerald S Falchook, Peter Rady, Sharon Hymes, et al.
Neuro-Oncology Advances
|
February 10, 2025
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma
Gerald S Falchook, James D Battiste, Amandeep Kalra, et al.
Cancer Immunology, Immunotherapy : CII
|
September 29, 2020
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Kyriakos P Papadopoulos, Nehal Lakhani, Gerald S Falchook, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 5, 2021
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
Wenyuan Xiong, Manja Friese-Hamim, Andreas Johne, et al.
Oncotarget
|
July 11, 2018
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors
Ishwaria M Subbiah, Chad Tang, Arvind Rao, et al.
ESMO Open
|
February 22, 2018
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
Kathleen N Moore, Todd M Bauer, Gerald S Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2014
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer
Gerald S Falchook, Nelson G Ordóñez, Christel C Bastida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2010
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
Ignacio Garrido-Laguna, Filip Janku, Gerald S Falchook, et al.
Page
of 14